Saravanan Raju

2 months ago | cell.com | Saravanan Raju |Sathvik Palakurty |Alan Sariol |Ngan Wagoner |Lucas Adams |Sean Hui | +3 more

Keywords alphavirus receptor structure pathogenesis therapy cryoelectron microscopy Introduction Alphaviruses are arthropod-transmitted viruses that infect many vertebrate hosts.1 The encephalitic alphaviruses, including Eastern equine encephalitic virus (EEEV), Venezuelan equine encephalitic virus (VEEV), and Western equine encephalitic virus (WEEV), are neurotropic in both horses and humans and cause lethality or long-term neurological sequelae.2 Whereas some bird species serve as enzootic...

Dec 22, 2023 | cell.com | Saravanan Raju |Lucas Adams |Michael Diamond |Immunotherapy Programs

Highlights Proteinaceous receptors bind distinct sites of the alphavirus glycoprotein to mediate efficient cellular entry. The cleft formed by E1–E2 heterodimers is utilized by the mammalian MXRA8 to bind Chikungunya virus (CHIKV) and LDLRAD3 to bind Venezuelan equine encephalitis virus (VEEV).

Nov 15, 2023 | biorxiv.org | Lucas Adams |Saravanan Raju |Hongming Ma |Theron Gilliland

AbstractThe very low-density lipoprotein receptor (VLDLR) is comprised of eight LDLR type A (LA) domains and supports entry of distantly related Eastern equine encephalitis (EEEV) and Semliki Forest (SFV) alphaviruses. Here, by resolving multiple cryo-electron microscopy structures of EEEV-VLDLR complexes and performing mutagenesis and functional studies, we show that EEEV uses multiple sites (E1/E2 cleft and E2 A domain) to engage different LA domains simultaneously.

Aug 15, 2023 | blogs.sap.com | Saravanan Raju

Single Sign-on configuration for S/4HANA 2021 with Azure Active Directory (Azure AD) for accessing SAP Fiori applications using SAML SSO mechanism. PrerequisitesTo get started, you need the following items:A Microsoft Azure AD subscription. SAP S/4HANA Application access to configure SSO (SAML2 Tcode)SAP NetWeaver V7.20 required at least.

May 17, 2023 | science.org | Ernest Moles |Sean Anderson |Tanes I. Lima |Saravanan Raju

AbstractChikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics of acute and chronic musculoskeletal disease. Here, we analyzed the human B cell response to a CHIKV-like particle–adjuvanted vaccine (PXVX0317) from samples obtained from a phase 2 clinical trial in humans (NCT03483961). Immunization with PXVX0317 induced high levels of neutralizing antibody in serum against CHIKV and circulating antigen–specific B cells up to 6 months after immunization.